ArticleBlood advances2026

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Joseph M Tuscano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.